ABMD - Better Buy for the Next 10 Years: Abiomed vs. Guardant Heath
Abiomed (NASDAQ: ABMD) and Guardant Health (NASDAQ: GH) both sport market caps just north of $13 billion, but these companies represent very different ways to invest in healthcare stocks for the next decade.
Abiomed is the maker of Impella, a temporarily implanted device meant to help protect the heart when it's been damaged or during complex procedures. Guardant Health, meanwhile, utilizes a blood test to perform a liquid biopsy to determine whether a patient has cancer, and if so, what treatment regimens would be best. The company's tests also detect "minimal residual disease" -- that is, "Is there still evidence of cancer and does the patient need more treatment?"
Image source: Getty Images
For further details see:
Better Buy for the Next 10 Years: Abiomed vs. Guardant Heath